Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma

Q: What does this research mean for the field?

Axicabtagene ciloleucel provides improved progression-free survival compared to tisagenlecleucel in patients aged over 70 years with large B-cell lymphoma. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Vanderson Rocha; Jarl E. Mooyaart; Ron Ram; Katherine Clesham; Michael Daskalakis; Anne Huynh; Victoria Potter; Sridhar Chaganti; Ludovic Gabellier; Eleni Tholouli; M. P. Collin; E. Nicholson; Rachel Protheroe; Jacob Passweg; Francis Ayuk; Dominik Schneidawind; Mi Kwon; Lucía López Corral; Robert Zeiser; Christof Scheid; Ibrahim Yakoub-Agha; Peter Dreger; Friedrich Stölzel; Jorinde Hoogenboom; Maiana Hamdan Melo Coelho; ANA ALARCON TOMAS; Florent Malard; Jürgen Kuball; A. Sureda; Ali Barzabachi; Annalisa Ruggeri

doi:10.3324/haematol.2026.300508

Key Points

To compare clinical outcomes, toxicities, and prognostic factors between tisagenlecleucel and axicabtagene ciloleucel in patients aged 70 years and older with relapsed or refractory large B-cell lymphoma.
Retrospective registry analysis of N=1,191 patients aged ≥70 years from the EBMT database (tisa-cel n=402; axi-cel n=789) with a median follow-up of 22.7 months.
Multivariable models adjusted for age, sex, performance status, disease status at infusion, prior transplantation, and infusion year.
Axicabtagene ciloleucel resulted in improved progression-free survival compared to tisagenlecleucel in patients aged ≥70 years with large B-cell lymphoma.
Day-30 any-grade cytokine release syndrome occurred in 62% of tisa-cel patients compared to 77% of axi-cel patients.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Registry cohort study demonstrates improved progression-free survival with axicabtagene ciloleucel over tisagenlecleucel in adults aged ≥70, highlighting key efficacy differences.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rocha et al. (2026) studied this question.

synapsesocial.com/papers/6a81794cf2fb91fc834ac70c https://doi.org/10.3324/haematol.2026.300508

View Full Paper

Ask AI

Bookmark

Share

Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading